Breaking News

You are here » Indian-Commodity  :  Corporate  :  Zydus Cadila receives final approval from USFDA for Mesalamine Delayed-Release Tablets

25-Jul2017

Zydus Cadila receives final approval from USFDA for Mesalamine Delayed-Release Tablets

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) for Mesalamine Delayed-Release Tablets in the strength of 800 mg. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.

The group has received 27 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Related News

View all news

IndiGo launches new offer for domestic, international flights: Report

InterGlobe Aviation (IndiGo) has reportedly launched new offer at Rs 899 for domestic flights and Rs 3,199 for international flights in its new sale. The 'Fare-tastic Winters!' offer is starting from November......

HDFC Bank to hike stake in CCIL

HDFC Bank will acquire 4% equity stake in Clearing Corporation of India (CCIL). The Bank currently holds 5% of the total equity capital of CCIL. Hence, it is proposed to increase the stake in CCIL from......

Indiabulls Housing Finance raises Rs 23,615 crore in last 2 months

Indiabulls Housing Finance has raised Rs 23,615 crore in the last 2 months from 32 financial institutions in various debt instruments, securitization and sanctions. Of the total of Rs 23,615 crore raised,......

Top News

View all news

Megastar Foods planning to incorporate subsidiary

Megastar Foods is planning to incorporate a subsidiary Company. The meeting of the Board of Directors of the company is scheduled to be held on November 27, 2018, to consider the same. Megastar Foods is......

Lupin launches generic Tetrabenazine Tablets

Lupin has launched Tetrabenazine Tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin's Tetrabenazine Tablets, 12.5 mg and 25......

UPL's arm signs definitive agreement to acquire entire stake of IBC

UPL's wholly owned subsidiary-- UPL Corporation, Mauritius has signed a definitive agreement to acquire directly or through its subsidiaries 100% of the shares of INDUSTRIAS BIOQUIM CENTROAMERICANA, SOCIEDAD......